<SEC-DOCUMENT>0001193125-20-320191.txt : 20201217
<SEC-HEADER>0001193125-20-320191.hdr.sgml : 20201217
<ACCEPTANCE-DATETIME>20201217171658
ACCESSION NUMBER:		0001193125-20-320191
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201217
FILED AS OF DATE:		20201217
DATE AS OF CHANGE:		20201217

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mereo Biopharma Group plc
		CENTRAL INDEX KEY:			0001719714
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38452
		FILM NUMBER:		201397061

	BUSINESS ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF
		BUSINESS PHONE:		4403330237300

	MAIL ADDRESS:	
		STREET 1:		ONE CAVENDISH PLACE
		STREET 2:		FOURTH FLOOR
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1G0QF
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d28476d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE&nbsp;SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2020 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-38452</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEREO BIOPHARMA GROUP PLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, One Cavendish Place,</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>London, W1G 0QF, United Kingdom</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Exhibit Index </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d28476dex991.htm">Press release dated December&nbsp;17, 2020. </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December&nbsp;17, 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEREO BIOPHARMA GROUP PLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Charles Sermon</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:&nbsp;Charles Sermon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:&nbsp;General Counsel</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d28476dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g28476dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED UNDER THE MARKET ABUSE REGULATION (EU) NO.
596/2014. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Mereo BioPharma and Ultragenyx
Announce Collaboration and License </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agreement for Setrusumab in Osteogenesis Imperfecta </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Ultragenyx&#146;s existing bone franchise </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Ultragenyx leads and funds development to approval; Mereo retains commercial rights in </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Europe, Ultragenyx commercializes in US and in rest of world </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Mereo receives $50&nbsp;million upfront and is eligible for milestones up to $254&nbsp;million </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>London, Redwood City, Calif., and Novato, Calif. &#151; December 17, 2020 &#151;</B> Mereo BioPharma Group plc (Nasdaq: MREO, AIM: MPH), a clinical stage
biopharmaceutical company focused on oncology and rare diseases, and Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare
diseases, today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI). Setrusumab is an investigational anti-sclerostin fully human monoclonal antibody that has
shown the ability to improve bone production and density leading to greater bone strength in animal models of OI. Data from a Phase 2b of setrusumab conducted by Mereo demonstrated a dose-dependent increase in bone formation, density, and strength
in adults with OI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Osteogenesis imperfecta is a rare and devastating genetic disease, with currently no approved therapies. We are proud to partner
with Ultragenyx to continue the development of setrusumab as potentially the first approved therapy for OI in both children and adults,&#148; said Dr.&nbsp;Denise Scots-Knight, Chief Executive Officer of Mereo. &#147;Following the positive data from
our Phase 2b ASTEROID study, we set out to find the right partner and we believe that Ultragenyx, with its proven track record of successfully developing and commercializing novel therapies for rare diseases, is ideally positioned to support the
further advancement of our innovative therapeutic candidate. We look forward to continuing to work closely with Ultragenyx to make setrusumab available to the OI community worldwide.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Setrusumab is a great complement to Ultragenyx&#146;s product portfolio and enables us to leverage the broad expertise and infrastructure we have
established in metabolic bone diseases with Crysvita,&#148; stated Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. &#147;Most importantly, setrusumab is a promising option for patients with osteogenesis imperfecta,
which is one of the most common genetic bone diseases associated with frequent bone fractures.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">OI is a group of genetic disorders including types I, III and IV, of which approximately <FONT
STYLE="white-space:nowrap">85-90%</FONT> are caused by mutations in the <I>COL1A1</I> or <I>COL1A2</I> genes leading to either a reduced amount of normal collagen or collagen with abnormal structure and changes in bone metabolism. Since collagen
molecules represent the foundation upon which bone is formed, these abnormalities lead to increased bone resorption, reduced bone mass, and bone fragility and weakness. Although the abnormal or deficient collagen weakens bone, these collagen
abnormalities also set off a maladaptive cascade of bone remodeling signals that enhance bone resorption, or the breaking down of bone, with inadequate production of new bone, which compounds the bone fragility. These genetic defects and their
consequences lead to systemic clinical manifestations such as decreased bone mass, bone brittleness leading to a high rate of fractures, including at atypical sites, or bone deformities, including abnormal spine curvature, as well as pain, decreased
mobility, and short stature. OI affects approximately 60,000 patients in the developed world and has no approved treatments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Setrusumab is a fully human
monoclonal antibody that inhibits sclerostin, a protein that acts on a key bone-signaling pathway and inhibits the activity of bone-forming cells. By blocking inhibitory effects of sclerostin, the anti-sclerostin antibody causes new bone formation,
increased production of collagen, and increased bone mineral density and strength. Sclerostin inhibition also reduces excessive bone resorption, further enhancing the impact on bone density. In various mouse models of OI, the use of anti-sclerostin
antibodies was shown to stimulate bone formation, improve bone mass and density, reduce bone fragility, increase long bone stiffness and strength, and reduce the number of fractures. Overall, improvements in bone mass and strength were enhanced when
an anti-sclerostin antibody was used in combination with bisphosphonates, the current standard of care in OI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mereo has completed the Phase 2b ASTEROID
study of setrusumab across three dose groups monthly for 12 months in 90 adults with OI types I, III, and IV. Results from the study indicated improvements in bone mineral density across multiple measures and at multiple anatomical sites on a
dose-dependent basis after 12 months. Improvements were also observed in serum P1NP (procollagen type I N propeptide), a biomarker of bone formation and direct measure of collagen production. The bone mineral density and P1NP results were consistent
across OI types studied. In addition, there was a dose-dependent improvement in trabecular bone architecture and bone strength by measuring wrist bone failure load and stiffness. In the per protocol population at the high dose, there was a trend
toward improvement of ankle failure load and a statistically significant improvement in ankle bone stiffness. While the study was not powered to show a difference in fracture rates, there was a trend toward a reduction in fractures in the highest
dose relative to the lower doses. In the study, setrusumab was generally well tolerated with no cardiac-related safety concerns observed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The companies
will expand and initially prioritize the development of setrusumab for pediatric patients with OI. Development plans are being finalized which may include changes to current study designs, and will require discussions with regulatory agencies, for a
pediatric Phase 2/3 study that first focuses on determining the optimal dose based on increases in collagen </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
production using serum P1NP levels and an acceptable safety profile. Following determination of the dose, the study is intended to adapt into a pivotal Phase 3 stage, evaluating fracture
reduction over an estimated 15 to 24 months as the primary endpoint pending regulatory review. The pediatric Phase 2/3 study is expected to start in 2021. A separate pivotal study is also being planned for adults with OI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Setrusumab has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), rare pediatric disease
designation from the FDA, and was accepted into the EMA&#146;s Priority Medicines program (PRIME). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the collaboration, Ultragenyx will
lead future global development of setrusumab in both pediatric and adult patients. Mereo granted Ultragenyx an exclusive license to develop and commercialize setrusumab in the US and rest of the world, excluding Europe where Mereo retains commercial
rights. Each party will be responsible for post-marketing commitments in their respective territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ultragenyx will make an upfront payment of
$50&nbsp;million to Mereo and will fund global development of the program until approval, and has agreed to pay a total of up to $254&nbsp;million upon achievement of certain clinical, regulatory, and commercial milestones. Ultragenyx will pay
tiered double digit percentage royalties to Mereo on net sales outside of Europe, and Mereo will pay a fixed double digit percentage royalty to Ultragenyx on net sales in Europe. Under the terms of its 2015 agreement with Novartis, Mereo will pay
Novartis a percentage of proceeds, subject to certain deductions, with Mereo receiving a substantial majority of the payments from Ultragenyx. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
completion of the transaction is subject to Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) review and the satisfaction of other customary closing conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Osteogenesis Imperfecta </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Osteogenesis Imperfecta
(OI) is a rare genetic disorder that is characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints, and weakened teeth. In severe cases, those with OI may experience hundreds of fractures in a lifetime.
In addition, people with OI often suffer muscle weakness, early hearing loss, fatigue, curved bones, scoliosis, respiratory problems, and short stature, leading to significant effects on overall health and quality of life. The majority of cases of
OI (estimated at approximately 90%) are caused by a dominant mutation in a gene coding for type I collagen, a key component of healthy bone. Current treatment of OI is supportive, focusing on minimizing fractures and maximizing mobility, but to
date, there are no FDA or EU approved treatments. OI is estimated to affect between 1 in 6,500 and 1 in 30,000 people globally. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Mereo Biopharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for
oncology and rare diseases. Mereo&#146;s lead oncology product candidate, etigilimab (Anti-TIGIT), has completed a Phase 1a dose escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in
combination with nivolumab in select tumor types. The company recently announced initiation of a Phase 1b/2 study of etigilimab in combination with an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PDL-1</FONT></FONT></FONT> in a range of different tumor types. Mereo&#146;s rare disease product portfolio consists of setrusumab, which
has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT>
clinical trial in patients with <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in <FONT STYLE="white-space:nowrap">COVID-19</FONT> respiratory disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Ultragenyx </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ultragenyx is a biopharmaceutical
company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high
unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is
led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx&#146;s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency and ensuring majority access to its therapies for patients who can benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ultragenyx&#146;s metabolic
bone product portfolio includes Crysvita<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (burosumab), which is approved by the FDA for the treatment of <FONT STYLE="white-space:nowrap">X-linked</FONT> hypophosphatemia (XLH) in adult and
pediatric patients six months of age and older and for FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric
patients 2 years of age and older. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on Ultragenyx, please visit the company&#146;s website at <U>www.ultragenyx.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person responsible for
arranging the release of this information on behalf of Mereo BioPharma Group plc is Charles Sermon, General Counsel of Mereo. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mereo BioPharma Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This Announcement contains &#147;forward-looking statements.&#148; All statements other than statements of historical fact contained in this Announcement
are forward-looking statements within the meaning of Section&nbsp;27A of the United States Securities Act of 1933, as amended and Section&nbsp;21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually
relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words &#147;believe,&#148; &#147;expect,&#148;
&#147;anticipate,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;foresee,&#148; &#147;should,&#148; &#147;would,&#148; &#147;could,&#148; &#147;may,&#148; &#147;estimate,&#148; &#147;outlook&#148; and similar expressions, including the negative
thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company&#146;s current expectations, beliefs and assumptions concerning future developments
and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be
those that it anticipates. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>All of the Company&#146;s forward-looking statements involve known and unknown risks and uncertainties some of which
are significant or beyond its control and involve assumptions that could cause actual results to differ materially from the Company&#146;s historical experience and its present expectations or projections.</I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>These forward-looking statements are subject to risks and uncertainties, including, among other things, those described in the Company&#146;s latest Annual
Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> Reports on Form <FONT STYLE="white-space:nowrap">6-K</FONT> and other documents filed from time to time by the Company with the United States Securities and Exchange Commission. The
Company wishes to caution investors not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except to the extent required by law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ultragenyx Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx&#146;s
expectations and projections regarding its future operating results and financial performance, anticipated cost or expense reductions,&nbsp;the timing, progress and plans for its clinical programs and clinical studies, future regulatory
interactions, and the components and timing of regulatory submissions are forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others, the effects from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the company&#146;s clinical activities, business and operating
</I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
results, risks related to reliance on third party partners to conduct certain activities on the company&#146;s behalf, uncertainty and potential delays related to clinical drug development,
smaller than anticipated market opportunities for the company&#146;s products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect sufficiency of existing cash, cash
equivalents and short-term investments to fund operations, the company&#146;s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential
of Ultragenyx&#146;s products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the&nbsp;Securities and
Exchange Commission&nbsp;on&nbsp;October 27, 2020, and its subsequent periodic reports filed with the&nbsp;Securities and Exchange Commission. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts</B>: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Mereo</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>+44 (0)333 023 7300</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Denise Scots-Knight, Chief Executive Officer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>N+1 Singer (Nominated Adviser and Broker to&nbsp;Mereo)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>+44 (0)20 7496 3081</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phil Davies</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Will Goode</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Burns McClellan (US Investor Relations Adviser to&nbsp;Mereo)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>+01 212 213 0006</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lisa Burns</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lee Roth</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>FTI Consulting (UK Public Relations Adviser to&nbsp;Mereo)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>+44 (0)20 3727 1000</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Simon Conway</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ciara Martin</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Investors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>investors@mereobiopharma.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ultragenyx </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Joshua Higa
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(415) <FONT STYLE="white-space:nowrap">475-6370</FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g28476dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g28476dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M-8RKS9TQPT(]#IEC5  H  X  Z5C<W44MAV,4BA: "@ H * "@ H * "@ H
M* "@ H * $(H :R*R%64%2,$$9S0KH&KG)ZOX TS49O.M]UE*>HC4;#_ ,!_
MPQ73#$3@<57!PJ:K1G'7_@#6[&3-M$MW&#D-&P5A^!_IFNR&+BU:2."6"J1=
MT.L[_P 8:)@&"]>)?X9XFD7\_P#Z]*4*$^J'&>(I]'^)JQ_$/5%PD^B"0]PN
MY<_F#6+P\%M+\CHCBJRWA^9)_;:ZH"9/ IN"?XO*W?J4J?91C]O^OO+6(JR_
MY=B1>'_[1E '@BVLT)YDFN",?\!7FLVTOM7+2E+>-C>L_!6E0,K2V%H=O.U(
M>#]=Q)_E6;F;QIHWK;3[.T %M:0P_P#7.,+_ "J+MFBBD60*10M !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 W;Z]* L@VTKA9"@8IA86@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
2@ H * "@ H * "@ H * /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
